Analyzing Diplomat Pharmacy (DPLO) & Its Competitors
Diplomat Pharmacy (NYSE: DPLO) is one of 23 publicly-traded companies in the “Food Retail & Distribution” industry, but how does it contrast to its competitors? We will compare Diplomat Pharmacy to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.
Earnings and Valuation
This table compares Diplomat Pharmacy and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Diplomat Pharmacy||$4.53 billion||$70.47 million||126.88|
|Diplomat Pharmacy Competitors||$21.46 billion||$1.01 billion||39.04|
Diplomat Pharmacy’s competitors have higher revenue and earnings than Diplomat Pharmacy. Diplomat Pharmacy is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
69.9% of Diplomat Pharmacy shares are owned by institutional investors. Comparatively, 56.2% of shares of all “Food Retail & Distribution” companies are owned by institutional investors. 30.2% of Diplomat Pharmacy shares are owned by insiders. Comparatively, 17.1% of shares of all “Food Retail & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Diplomat Pharmacy and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Diplomat Pharmacy Competitors||0.80%||32.79%||4.17%|
Risk and Volatility
Diplomat Pharmacy has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Diplomat Pharmacy’s competitors have a beta of 0.93, suggesting that their average share price is 7% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Diplomat Pharmacy and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Diplomat Pharmacy Competitors||644||1344||1391||22||2.23|
Diplomat Pharmacy currently has a consensus price target of $19.16, indicating a potential downside of 11.19%. As a group, “Food Retail & Distribution” companies have a potential upside of 4.09%. Given Diplomat Pharmacy’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Diplomat Pharmacy has less favorable growth aspects than its competitors.
Diplomat Pharmacy competitors beat Diplomat Pharmacy on 9 of the 13 factors compared.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.